Grail stock jumps 33% ahead of FDA multi-cancer blood test review
Grail shares rose 33% ahead of an FDA advisory panel meeting this week to evaluate premarket approval for its blood test designed to detect multiple cancer types early.
Shares of Grail surged ahead of the diagnostic company's meeting with the Food and Drug Administration this week to assess premarket approval for its flagship blood test designed to detect multiple types of cancer earlier. An FDA advisory panel is set to meet on Wednesday to review Grail's application.